nodes	percent_of_prediction	percent_of_DWPC	metapath
Orlistat—CYP3A4—Fingolimod—multiple sclerosis	0.0384	0.246	CbGbCtD
Orlistat—CYP3A4—Methylprednisolone—multiple sclerosis	0.0248	0.158	CbGbCtD
Orlistat—CYP3A4—Triamcinolone—multiple sclerosis	0.0188	0.12	CbGbCtD
Orlistat—CYP3A4—Mitoxantrone—multiple sclerosis	0.0181	0.115	CbGbCtD
Orlistat—CYP3A4—Betamethasone—multiple sclerosis	0.0161	0.103	CbGbCtD
Orlistat—CYP3A4—Prednisolone—multiple sclerosis	0.0159	0.102	CbGbCtD
Orlistat—CYP3A4—Prednisone—multiple sclerosis	0.015	0.0959	CbGbCtD
Orlistat—ABHD12—retina—multiple sclerosis	0.00989	0.0544	CbGeAlD
Orlistat—DAGLA—nervous system—multiple sclerosis	0.00975	0.0536	CbGeAlD
Orlistat—DAGLA—central nervous system—multiple sclerosis	0.00939	0.0516	CbGeAlD
Orlistat—CYP3A4—Dexamethasone—multiple sclerosis	0.00936	0.0599	CbGbCtD
Orlistat—DAGLA—cerebellum—multiple sclerosis	0.00917	0.0504	CbGeAlD
Orlistat—PLA2G7—medulla oblongata—multiple sclerosis	0.00813	0.0447	CbGeAlD
Orlistat—ABHD16A—medulla oblongata—multiple sclerosis	0.00762	0.0419	CbGeAlD
Orlistat—DAGLA—brain—multiple sclerosis	0.00745	0.041	CbGeAlD
Orlistat—PLA2G7—midbrain—multiple sclerosis	0.00743	0.0408	CbGeAlD
Orlistat—PLA2G7—spinal cord—multiple sclerosis	0.00725	0.0398	CbGeAlD
Orlistat—ABHD12—medulla oblongata—multiple sclerosis	0.00714	0.0393	CbGeAlD
Orlistat—DAGLB—cerebellum—multiple sclerosis	0.00711	0.0391	CbGeAlD
Orlistat—ABHD16A—midbrain—multiple sclerosis	0.00697	0.0383	CbGeAlD
Orlistat—ABHD16A—spinal cord—multiple sclerosis	0.0068	0.0374	CbGeAlD
Orlistat—ABHD12—midbrain—multiple sclerosis	0.00653	0.0359	CbGeAlD
Orlistat—ABHD12—spinal cord—multiple sclerosis	0.00637	0.035	CbGeAlD
Orlistat—FASN—medulla oblongata—multiple sclerosis	0.006	0.033	CbGeAlD
Orlistat—DAGLB—brain—multiple sclerosis	0.00578	0.0318	CbGeAlD
Orlistat—FASN—midbrain—multiple sclerosis	0.00548	0.0301	CbGeAlD
Orlistat—ABHD16A—cerebellum—multiple sclerosis	0.00539	0.0296	CbGeAlD
Orlistat—FASN—spinal cord—multiple sclerosis	0.00535	0.0294	CbGeAlD
Orlistat—ABHD12—cerebellum—multiple sclerosis	0.00505	0.0278	CbGeAlD
Orlistat—PLA2G7—brain—multiple sclerosis	0.00467	0.0257	CbGeAlD
Orlistat—PLA2G4A—Raltitrexed—Methotrexate—multiple sclerosis	0.00443	0.417	CbGdCrCtD
Orlistat—FASN—cerebellum—multiple sclerosis	0.00424	0.0233	CbGeAlD
Orlistat—ABHD12—brain—multiple sclerosis	0.0041	0.0226	CbGeAlD
Orlistat—FASN—brain—multiple sclerosis	0.00344	0.0189	CbGeAlD
Orlistat—PLA2G4A—medulla oblongata—multiple sclerosis	0.00288	0.0158	CbGeAlD
Orlistat—PLA2G4A—midbrain—multiple sclerosis	0.00263	0.0145	CbGeAlD
Orlistat—PLA2G4A—spinal cord—multiple sclerosis	0.00257	0.0141	CbGeAlD
Orlistat—FASN—Azacitidine—Cladribine—multiple sclerosis	0.00251	0.236	CbGdCrCtD
Orlistat—PLA2G4A—nervous system—multiple sclerosis	0.00217	0.0119	CbGeAlD
Orlistat—PLA2G4A—central nervous system—multiple sclerosis	0.00208	0.0115	CbGeAlD
Orlistat—PLA2G4A—brain—multiple sclerosis	0.00166	0.0091	CbGeAlD
Orlistat—CYP3A4—nervous system—multiple sclerosis	0.000714	0.00393	CbGeAlD
Orlistat—CYP3A4—central nervous system—multiple sclerosis	0.000688	0.00378	CbGeAlD
Orlistat—Convulsion—Triamcinolone—multiple sclerosis	0.000392	0.000975	CcSEcCtD
Orlistat—Convulsion—Methylprednisolone—multiple sclerosis	0.000391	0.000973	CcSEcCtD
Orlistat—Urticaria—Mitoxantrone—multiple sclerosis	0.000388	0.000967	CcSEcCtD
Orlistat—Hyperhidrosis—Prednisolone—multiple sclerosis	0.000388	0.000966	CcSEcCtD
Orlistat—PLA2G4A—Dexamethasone—Methylprednisolone—multiple sclerosis	0.000387	0.0365	CbGdCrCtD
Orlistat—PLA2G4A—Betamethasone—Methylprednisolone—multiple sclerosis	0.000387	0.0365	CbGdCrCtD
Orlistat—Body temperature increased—Mitoxantrone—multiple sclerosis	0.000386	0.000963	CcSEcCtD
Orlistat—Abdominal pain—Mitoxantrone—multiple sclerosis	0.000386	0.000963	CcSEcCtD
Orlistat—Myalgia—Triamcinolone—multiple sclerosis	0.000385	0.000958	CcSEcCtD
Orlistat—Vomiting—Azathioprine—multiple sclerosis	0.000384	0.000958	CcSEcCtD
Orlistat—Myalgia—Methylprednisolone—multiple sclerosis	0.000384	0.000956	CcSEcCtD
Orlistat—Anxiety—Methylprednisolone—multiple sclerosis	0.000383	0.000953	CcSEcCtD
Orlistat—Infestation NOS—Methotrexate—multiple sclerosis	0.000382	0.000951	CcSEcCtD
Orlistat—Infestation—Methotrexate—multiple sclerosis	0.000382	0.000951	CcSEcCtD
Orlistat—Rash—Azathioprine—multiple sclerosis	0.000381	0.00095	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000381	0.00095	CcSEcCtD
Orlistat—PLA2G4A—Dexamethasone—Betamethasone—multiple sclerosis	0.000381	0.0359	CbGdCrCtD
Orlistat—PLA2G4A—Betamethasone—Dexamethasone—multiple sclerosis	0.000381	0.0359	CbGdCrCtD
Orlistat—Dermatitis—Azathioprine—multiple sclerosis	0.000381	0.000949	CcSEcCtD
Orlistat—Depression—Methotrexate—multiple sclerosis	0.000381	0.000948	CcSEcCtD
Orlistat—Ill-defined disorder—Dexamethasone—multiple sclerosis	0.00038	0.000948	CcSEcCtD
Orlistat—Ill-defined disorder—Betamethasone—multiple sclerosis	0.00038	0.000948	CcSEcCtD
Orlistat—Discomfort—Triamcinolone—multiple sclerosis	0.00038	0.000947	CcSEcCtD
Orlistat—Discomfort—Methylprednisolone—multiple sclerosis	0.000379	0.000945	CcSEcCtD
Orlistat—Headache—Azathioprine—multiple sclerosis	0.000379	0.000944	CcSEcCtD
Orlistat—Dry mouth—Triamcinolone—multiple sclerosis	0.000376	0.000937	CcSEcCtD
Orlistat—Renal failure—Methotrexate—multiple sclerosis	0.000375	0.000935	CcSEcCtD
Orlistat—Angioedema—Betamethasone—multiple sclerosis	0.000375	0.000933	CcSEcCtD
Orlistat—Angioedema—Dexamethasone—multiple sclerosis	0.000375	0.000933	CcSEcCtD
Orlistat—PLA2G4A—Betamethasone—Triamcinolone—multiple sclerosis	0.000372	0.0351	CbGdCrCtD
Orlistat—PLA2G4A—Dexamethasone—Triamcinolone—multiple sclerosis	0.000372	0.0351	CbGdCrCtD
Orlistat—Immune system disorder—Prednisone—multiple sclerosis	0.00037	0.000923	CcSEcCtD
Orlistat—Malaise—Betamethasone—multiple sclerosis	0.00037	0.000921	CcSEcCtD
Orlistat—Malaise—Dexamethasone—multiple sclerosis	0.00037	0.000921	CcSEcCtD
Orlistat—Oedema—Triamcinolone—multiple sclerosis	0.000369	0.000919	CcSEcCtD
Orlistat—Anaphylactic shock—Triamcinolone—multiple sclerosis	0.000369	0.000919	CcSEcCtD
Orlistat—Vertigo—Betamethasone—multiple sclerosis	0.000368	0.000918	CcSEcCtD
Orlistat—Vertigo—Dexamethasone—multiple sclerosis	0.000368	0.000918	CcSEcCtD
Orlistat—Anaphylactic shock—Methylprednisolone—multiple sclerosis	0.000368	0.000917	CcSEcCtD
Orlistat—Infection—Triamcinolone—multiple sclerosis	0.000366	0.000913	CcSEcCtD
Orlistat—Infection—Methylprednisolone—multiple sclerosis	0.000366	0.000911	CcSEcCtD
Orlistat—Insomnia—Prednisolone—multiple sclerosis	0.000363	0.000903	CcSEcCtD
Orlistat—Alopecia—Prednisone—multiple sclerosis	0.000362	0.000903	CcSEcCtD
Orlistat—Hepatobiliary disease—Methotrexate—multiple sclerosis	0.000361	0.0009	CcSEcCtD
Orlistat—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000361	0.000899	CcSEcCtD
Orlistat—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.00036	0.000897	CcSEcCtD
Orlistat—Paraesthesia—Prednisolone—multiple sclerosis	0.00036	0.000897	CcSEcCtD
Orlistat—Mental disorder—Prednisone—multiple sclerosis	0.000359	0.000895	CcSEcCtD
Orlistat—Nausea—Azathioprine—multiple sclerosis	0.000359	0.000895	CcSEcCtD
Orlistat—Skin disorder—Methylprednisolone—multiple sclerosis	0.000357	0.00089	CcSEcCtD
Orlistat—Malnutrition—Prednisone—multiple sclerosis	0.000357	0.000889	CcSEcCtD
Orlistat—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.000357	0.000888	CcSEcCtD
Orlistat—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.000356	0.000886	CcSEcCtD
Orlistat—Convulsion—Dexamethasone—multiple sclerosis	0.000355	0.000885	CcSEcCtD
Orlistat—Convulsion—Betamethasone—multiple sclerosis	0.000355	0.000885	CcSEcCtD
Orlistat—PLA2G4A—Dexamethasone—Prednisone—multiple sclerosis	0.000353	0.0333	CbGdCrCtD
Orlistat—PLA2G4A—Betamethasone—Prednisone—multiple sclerosis	0.000353	0.0333	CbGdCrCtD
Orlistat—Asthenia—Mitoxantrone—multiple sclerosis	0.000351	0.000874	CcSEcCtD
Orlistat—Myalgia—Dexamethasone—multiple sclerosis	0.000349	0.000869	CcSEcCtD
Orlistat—Myalgia—Betamethasone—multiple sclerosis	0.000349	0.000869	CcSEcCtD
Orlistat—Anxiety—Betamethasone—multiple sclerosis	0.000348	0.000866	CcSEcCtD
Orlistat—Anxiety—Dexamethasone—multiple sclerosis	0.000348	0.000866	CcSEcCtD
Orlistat—Discomfort—Dexamethasone—multiple sclerosis	0.000345	0.000859	CcSEcCtD
Orlistat—Discomfort—Betamethasone—multiple sclerosis	0.000345	0.000859	CcSEcCtD
Orlistat—PLA2G4A—Betamethasone—Prednisolone—multiple sclerosis	0.000345	0.0325	CbGdCrCtD
Orlistat—PLA2G4A—Dexamethasone—Prednisolone—multiple sclerosis	0.000345	0.0325	CbGdCrCtD
Orlistat—Haemoglobin—Methotrexate—multiple sclerosis	0.000345	0.000858	CcSEcCtD
Orlistat—Pain—Prednisolone—multiple sclerosis	0.000343	0.000854	CcSEcCtD
Orlistat—Haemorrhage—Methotrexate—multiple sclerosis	0.000343	0.000854	CcSEcCtD
Orlistat—Hepatitis—Methotrexate—multiple sclerosis	0.000343	0.000854	CcSEcCtD
Orlistat—Pharyngitis—Methotrexate—multiple sclerosis	0.00034	0.000847	CcSEcCtD
Orlistat—Urinary tract disorder—Methotrexate—multiple sclerosis	0.000339	0.000843	CcSEcCtD
Orlistat—Vision blurred—Prednisone—multiple sclerosis	0.000337	0.000838	CcSEcCtD
Orlistat—Urethral disorder—Methotrexate—multiple sclerosis	0.000336	0.000837	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000336	0.000837	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000335	0.000835	CcSEcCtD
Orlistat—Oedema—Betamethasone—multiple sclerosis	0.000335	0.000834	CcSEcCtD
Orlistat—Oedema—Dexamethasone—multiple sclerosis	0.000335	0.000834	CcSEcCtD
Orlistat—Anaphylactic shock—Betamethasone—multiple sclerosis	0.000335	0.000834	CcSEcCtD
Orlistat—Anaphylactic shock—Dexamethasone—multiple sclerosis	0.000335	0.000834	CcSEcCtD
Orlistat—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000334	0.000833	CcSEcCtD
Orlistat—Insomnia—Triamcinolone—multiple sclerosis	0.000334	0.000831	CcSEcCtD
Orlistat—Insomnia—Methylprednisolone—multiple sclerosis	0.000333	0.000829	CcSEcCtD
Orlistat—Infection—Dexamethasone—multiple sclerosis	0.000332	0.000828	CcSEcCtD
Orlistat—Infection—Betamethasone—multiple sclerosis	0.000332	0.000828	CcSEcCtD
Orlistat—Ill-defined disorder—Prednisone—multiple sclerosis	0.000331	0.000825	CcSEcCtD
Orlistat—Paraesthesia—Triamcinolone—multiple sclerosis	0.000331	0.000825	CcSEcCtD
Orlistat—Feeling abnormal—Prednisolone—multiple sclerosis	0.00033	0.000823	CcSEcCtD
Orlistat—Paraesthesia—Methylprednisolone—multiple sclerosis	0.00033	0.000823	CcSEcCtD
Orlistat—Nervous system disorder—Betamethasone—multiple sclerosis	0.000328	0.000817	CcSEcCtD
Orlistat—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000328	0.000817	CcSEcCtD
Orlistat—Angioedema—Prednisone—multiple sclerosis	0.000326	0.000813	CcSEcCtD
Orlistat—Dyspepsia—Triamcinolone—multiple sclerosis	0.000325	0.000809	CcSEcCtD
Orlistat—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000324	0.000807	CcSEcCtD
Orlistat—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.000323	0.000806	CcSEcCtD
Orlistat—Hyperhidrosis—Betamethasone—multiple sclerosis	0.000323	0.000806	CcSEcCtD
Orlistat—Malaise—Prednisone—multiple sclerosis	0.000322	0.000802	CcSEcCtD
Orlistat—Vertigo—Prednisone—multiple sclerosis	0.000321	0.000799	CcSEcCtD
Orlistat—Urticaria—Prednisolone—multiple sclerosis	0.000319	0.000794	CcSEcCtD
Orlistat—Fatigue—Triamcinolone—multiple sclerosis	0.000318	0.000792	CcSEcCtD
Orlistat—Fatigue—Methylprednisolone—multiple sclerosis	0.000317	0.00079	CcSEcCtD
Orlistat—Pain—Triamcinolone—multiple sclerosis	0.000315	0.000786	CcSEcCtD
Orlistat—Vomiting—Mitoxantrone—multiple sclerosis	0.000311	0.000774	CcSEcCtD
Orlistat—Immune system disorder—Methotrexate—multiple sclerosis	0.00031	0.000771	CcSEcCtD
Orlistat—Convulsion—Prednisone—multiple sclerosis	0.000309	0.000771	CcSEcCtD
Orlistat—Mediastinal disorder—Methotrexate—multiple sclerosis	0.000309	0.00077	CcSEcCtD
Orlistat—Rash—Mitoxantrone—multiple sclerosis	0.000308	0.000768	CcSEcCtD
Orlistat—Dermatitis—Mitoxantrone—multiple sclerosis	0.000308	0.000767	CcSEcCtD
Orlistat—Headache—Mitoxantrone—multiple sclerosis	0.000306	0.000763	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000305	0.000759	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000305	0.000759	CcSEcCtD
Orlistat—Myalgia—Prednisone—multiple sclerosis	0.000304	0.000757	CcSEcCtD
Orlistat—Feeling abnormal—Triamcinolone—multiple sclerosis	0.000304	0.000757	CcSEcCtD
Orlistat—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000303	0.000755	CcSEcCtD
Orlistat—Anxiety—Prednisone—multiple sclerosis	0.000303	0.000755	CcSEcCtD
Orlistat—Alopecia—Methotrexate—multiple sclerosis	0.000303	0.000755	CcSEcCtD
Orlistat—Insomnia—Betamethasone—multiple sclerosis	0.000303	0.000754	CcSEcCtD
Orlistat—Insomnia—Dexamethasone—multiple sclerosis	0.000303	0.000754	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000302	0.000752	CcSEcCtD
Orlistat—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000301	0.00075	CcSEcCtD
Orlistat—Paraesthesia—Betamethasone—multiple sclerosis	0.0003	0.000748	CcSEcCtD
Orlistat—Paraesthesia—Dexamethasone—multiple sclerosis	0.0003	0.000748	CcSEcCtD
Orlistat—Discomfort—Prednisone—multiple sclerosis	0.0003	0.000748	CcSEcCtD
Orlistat—Mental disorder—Methotrexate—multiple sclerosis	0.0003	0.000748	CcSEcCtD
Orlistat—Malnutrition—Methotrexate—multiple sclerosis	0.000298	0.000743	CcSEcCtD
Orlistat—Hypersensitivity—Prednisolone—multiple sclerosis	0.000295	0.000736	CcSEcCtD
Orlistat—Dyspepsia—Betamethasone—multiple sclerosis	0.000295	0.000734	CcSEcCtD
Orlistat—Dyspepsia—Dexamethasone—multiple sclerosis	0.000295	0.000734	CcSEcCtD
Orlistat—Urticaria—Triamcinolone—multiple sclerosis	0.000293	0.00073	CcSEcCtD
Orlistat—Urticaria—Methylprednisolone—multiple sclerosis	0.000292	0.000728	CcSEcCtD
Orlistat—Dysgeusia—Methotrexate—multiple sclerosis	0.000292	0.000728	CcSEcCtD
Orlistat—Body temperature increased—Triamcinolone—multiple sclerosis	0.000292	0.000726	CcSEcCtD
Orlistat—Anaphylactic shock—Prednisone—multiple sclerosis	0.000291	0.000726	CcSEcCtD
Orlistat—Oedema—Prednisone—multiple sclerosis	0.000291	0.000726	CcSEcCtD
Orlistat—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000291	0.000725	CcSEcCtD
Orlistat—Decreased appetite—Betamethasone—multiple sclerosis	0.000291	0.000725	CcSEcCtD
Orlistat—Decreased appetite—Dexamethasone—multiple sclerosis	0.000291	0.000725	CcSEcCtD
Orlistat—Nausea—Mitoxantrone—multiple sclerosis	0.00029	0.000723	CcSEcCtD
Orlistat—Infection—Prednisone—multiple sclerosis	0.00029	0.000721	CcSEcCtD
Orlistat—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000289	0.00072	CcSEcCtD
Orlistat—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000289	0.00072	CcSEcCtD
Orlistat—DAGLA—GPCR downstream signaling—IL2RA—multiple sclerosis	0.000289	0.00116	CbGpPWpGaD
Orlistat—Back pain—Methotrexate—multiple sclerosis	0.000289	0.000719	CcSEcCtD
Orlistat—Fatigue—Betamethasone—multiple sclerosis	0.000288	0.000719	CcSEcCtD
Orlistat—Fatigue—Dexamethasone—multiple sclerosis	0.000288	0.000719	CcSEcCtD
Orlistat—Pain—Betamethasone—multiple sclerosis	0.000286	0.000713	CcSEcCtD
Orlistat—Pain—Dexamethasone—multiple sclerosis	0.000286	0.000713	CcSEcCtD
Orlistat—Nervous system disorder—Prednisone—multiple sclerosis	0.000286	0.000712	CcSEcCtD
Orlistat—Skin disorder—Prednisone—multiple sclerosis	0.000283	0.000705	CcSEcCtD
Orlistat—Hyperhidrosis—Prednisone—multiple sclerosis	0.000282	0.000702	CcSEcCtD
Orlistat—Vision blurred—Methotrexate—multiple sclerosis	0.000281	0.000701	CcSEcCtD
Orlistat—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—MAPK1—multiple sclerosis	0.00028	0.00112	CbGpPWpGaD
Orlistat—Ill-defined disorder—Methotrexate—multiple sclerosis	0.000277	0.00069	CcSEcCtD
Orlistat—Feeling abnormal—Dexamethasone—multiple sclerosis	0.000276	0.000687	CcSEcCtD
Orlistat—Feeling abnormal—Betamethasone—multiple sclerosis	0.000276	0.000687	CcSEcCtD
Orlistat—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000274	0.000682	CcSEcCtD
Orlistat—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000274	0.000682	CcSEcCtD
Orlistat—PNLIP—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	0.000273	0.00109	CbGpPWpGaD
Orlistat—PLA2G4A—Endothelins—MAPK1—multiple sclerosis	0.000273	0.00109	CbGpPWpGaD
Orlistat—FASN—Disease—RPL5—multiple sclerosis	0.000272	0.00109	CbGpPWpGaD
Orlistat—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000272	0.000677	CcSEcCtD
Orlistat—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000271	0.000675	CcSEcCtD
Orlistat—DAGLB—Signaling Pathways—CCL3—multiple sclerosis	0.00027	0.00108	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CCL3—multiple sclerosis	0.00027	0.00108	CbGpPWpGaD
Orlistat—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000269	0.00108	CbGpPWpGaD
Orlistat—Malaise—Methotrexate—multiple sclerosis	0.000269	0.00067	CcSEcCtD
Orlistat—Vertigo—Methotrexate—multiple sclerosis	0.000268	0.000668	CcSEcCtD
Orlistat—DAGLB—Hemostasis—IL2—multiple sclerosis	0.000268	0.00107	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—IL2—multiple sclerosis	0.000268	0.00107	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—CCR5—multiple sclerosis	0.000266	0.00107	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—CCR5—multiple sclerosis	0.000266	0.00107	CbGpPWpGaD
Orlistat—Urticaria—Dexamethasone—multiple sclerosis	0.000266	0.000662	CcSEcCtD
Orlistat—Urticaria—Betamethasone—multiple sclerosis	0.000266	0.000662	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.000265	0.000661	CcSEcCtD
Orlistat—Dizziness—Prednisolone—multiple sclerosis	0.000265	0.000661	CcSEcCtD
Orlistat—Asthenia—Triamcinolone—multiple sclerosis	0.000265	0.000659	CcSEcCtD
Orlistat—Abdominal pain—Dexamethasone—multiple sclerosis	0.000265	0.000659	CcSEcCtD
Orlistat—Body temperature increased—Dexamethasone—multiple sclerosis	0.000265	0.000659	CcSEcCtD
Orlistat—Body temperature increased—Betamethasone—multiple sclerosis	0.000265	0.000659	CcSEcCtD
Orlistat—Abdominal pain—Betamethasone—multiple sclerosis	0.000265	0.000659	CcSEcCtD
Orlistat—Asthenia—Methylprednisolone—multiple sclerosis	0.000264	0.000658	CcSEcCtD
Orlistat—Insomnia—Prednisone—multiple sclerosis	0.000264	0.000657	CcSEcCtD
Orlistat—PLA2G4A—AGE/RAGE pathway—MAPK1—multiple sclerosis	0.000263	0.00105	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—IL2RA—multiple sclerosis	0.000262	0.00105	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—IL2RA—multiple sclerosis	0.000262	0.00105	CbGpPWpGaD
Orlistat—Paraesthesia—Prednisone—multiple sclerosis	0.000262	0.000652	CcSEcCtD
Orlistat—Pruritus—Triamcinolone—multiple sclerosis	0.000261	0.00065	CcSEcCtD
Orlistat—Cough—Methotrexate—multiple sclerosis	0.00026	0.000649	CcSEcCtD
Orlistat—FASN—Disease—SLC11A1—multiple sclerosis	0.00026	0.00104	CbGpPWpGaD
Orlistat—Pruritus—Methylprednisolone—multiple sclerosis	0.00026	0.000648	CcSEcCtD
Orlistat—DAGLA—Signaling Pathways—PTGER4—multiple sclerosis	0.00026	0.00104	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—PTGER4—multiple sclerosis	0.00026	0.00104	CbGpPWpGaD
Orlistat—Convulsion—Methotrexate—multiple sclerosis	0.000259	0.000644	CcSEcCtD
Orlistat—Dyspepsia—Prednisone—multiple sclerosis	0.000257	0.000639	CcSEcCtD
Orlistat—DAGLA—Signaling Pathways—PGR—multiple sclerosis	0.000256	0.00102	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—PGR—multiple sclerosis	0.000256	0.00102	CbGpPWpGaD
Orlistat—Myalgia—Methotrexate—multiple sclerosis	0.000254	0.000633	CcSEcCtD
Orlistat—Chest pain—Methotrexate—multiple sclerosis	0.000254	0.000633	CcSEcCtD
Orlistat—Decreased appetite—Prednisone—multiple sclerosis	0.000253	0.000631	CcSEcCtD
Orlistat—Rash—Prednisolone—multiple sclerosis	0.000253	0.00063	CcSEcCtD
Orlistat—Dermatitis—Prednisolone—multiple sclerosis	0.000253	0.000629	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000252	0.000628	CcSEcCtD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	0.000252	0.00101	CbGpPWpGaD
Orlistat—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000252	0.000627	CcSEcCtD
Orlistat—Fatigue—Prednisone—multiple sclerosis	0.000251	0.000626	CcSEcCtD
Orlistat—Headache—Prednisolone—multiple sclerosis	0.000251	0.000626	CcSEcCtD
Orlistat—Discomfort—Methotrexate—multiple sclerosis	0.000251	0.000625	CcSEcCtD
Orlistat—DAGLA—Signaling Pathways—CXCR3—multiple sclerosis	0.000251	0.001	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CXCR3—multiple sclerosis	0.000251	0.001	CbGpPWpGaD
Orlistat—PNLIP—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	0.000249	0.000998	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CD28—multiple sclerosis	0.000248	0.000995	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CD28—multiple sclerosis	0.000248	0.000995	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CCR2—multiple sclerosis	0.000244	0.000977	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CCR2—multiple sclerosis	0.000244	0.000977	CbGpPWpGaD
Orlistat—Dizziness—Triamcinolone—multiple sclerosis	0.000244	0.000607	CcSEcCtD
Orlistat—Anaphylactic shock—Methotrexate—multiple sclerosis	0.000244	0.000607	CcSEcCtD
Orlistat—Dizziness—Methylprednisolone—multiple sclerosis	0.000243	0.000606	CcSEcCtD
Orlistat—Infection—Methotrexate—multiple sclerosis	0.000242	0.000603	CcSEcCtD
Orlistat—Feeling abnormal—Prednisone—multiple sclerosis	0.00024	0.000598	CcSEcCtD
Orlistat—Asthenia—Dexamethasone—multiple sclerosis	0.00024	0.000598	CcSEcCtD
Orlistat—Asthenia—Betamethasone—multiple sclerosis	0.00024	0.000598	CcSEcCtD
Orlistat—Nervous system disorder—Methotrexate—multiple sclerosis	0.000239	0.000595	CcSEcCtD
Orlistat—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000238	0.000594	CcSEcCtD
Orlistat—Nausea—Prednisolone—multiple sclerosis	0.000238	0.000593	CcSEcCtD
Orlistat—Pruritus—Betamethasone—multiple sclerosis	0.000237	0.00059	CcSEcCtD
Orlistat—Pruritus—Dexamethasone—multiple sclerosis	0.000237	0.00059	CcSEcCtD
Orlistat—Skin disorder—Methotrexate—multiple sclerosis	0.000237	0.000589	CcSEcCtD
Orlistat—PNLIP—Metabolism—BCHE—multiple sclerosis	0.000236	0.000943	CbGpPWpGaD
Orlistat—Hyperhidrosis—Methotrexate—multiple sclerosis	0.000235	0.000586	CcSEcCtD
Orlistat—Vomiting—Triamcinolone—multiple sclerosis	0.000234	0.000584	CcSEcCtD
Orlistat—Vomiting—Methylprednisolone—multiple sclerosis	0.000234	0.000583	CcSEcCtD
Orlistat—PLA2G4A—Metabolism—SRM—multiple sclerosis	0.000233	0.000934	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—SELE—multiple sclerosis	0.000233	0.000932	CbGpPWpGaD
Orlistat—Rash—Triamcinolone—multiple sclerosis	0.000233	0.000579	CcSEcCtD
Orlistat—Dermatitis—Triamcinolone—multiple sclerosis	0.000232	0.000579	CcSEcCtD
Orlistat—Rash—Methylprednisolone—multiple sclerosis	0.000232	0.000578	CcSEcCtD
Orlistat—Dermatitis—Methylprednisolone—multiple sclerosis	0.000232	0.000577	CcSEcCtD
Orlistat—Urticaria—Prednisone—multiple sclerosis	0.000232	0.000577	CcSEcCtD
Orlistat—Headache—Triamcinolone—multiple sclerosis	0.000231	0.000575	CcSEcCtD
Orlistat—Headache—Methylprednisolone—multiple sclerosis	0.000231	0.000574	CcSEcCtD
Orlistat—Body temperature increased—Prednisone—multiple sclerosis	0.00023	0.000574	CcSEcCtD
Orlistat—Abdominal pain—Prednisone—multiple sclerosis	0.00023	0.000574	CcSEcCtD
Orlistat—DAGLB—GPCR downstream signaling—POMC—multiple sclerosis	0.000229	0.000917	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—POMC—multiple sclerosis	0.000229	0.000917	CbGpPWpGaD
Orlistat—Diarrhoea—Dexamethasone—multiple sclerosis	0.000229	0.00057	CcSEcCtD
Orlistat—Diarrhoea—Betamethasone—multiple sclerosis	0.000229	0.00057	CcSEcCtD
Orlistat—FASN—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	0.000225	0.000902	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CNR1—multiple sclerosis	0.000225	0.000901	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CNR1—multiple sclerosis	0.000225	0.000901	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	0.000225	0.000901	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	0.000225	0.000901	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CCL3—multiple sclerosis	0.000223	0.000895	CbGpPWpGaD
Orlistat—PLA2G4A—Opioid Signalling—MAPK1—multiple sclerosis	0.000223	0.000894	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—IL2RA—multiple sclerosis	0.000223	0.000893	CbGpPWpGaD
Orlistat—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.000222	0.000553	CcSEcCtD
Orlistat—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000222	0.000889	CbGpPWpGaD
Orlistat—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000222	0.000889	CbGpPWpGaD
Orlistat—Dizziness—Dexamethasone—multiple sclerosis	0.000221	0.000551	CcSEcCtD
Orlistat—Dizziness—Betamethasone—multiple sclerosis	0.000221	0.000551	CcSEcCtD
Orlistat—Insomnia—Methotrexate—multiple sclerosis	0.00022	0.000549	CcSEcCtD
Orlistat—Nausea—Triamcinolone—multiple sclerosis	0.000219	0.000546	CcSEcCtD
Orlistat—Paraesthesia—Methotrexate—multiple sclerosis	0.000219	0.000545	CcSEcCtD
Orlistat—PLA2G4A—Signaling by GPCR—S1PR1—multiple sclerosis	0.000219	0.000876	CbGpPWpGaD
Orlistat—Nausea—Methylprednisolone—multiple sclerosis	0.000219	0.000544	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—PTGER4—multiple sclerosis	0.000215	0.000862	CbGpPWpGaD
Orlistat—Hypersensitivity—Prednisone—multiple sclerosis	0.000215	0.000535	CcSEcCtD
Orlistat—Dyspepsia—Methotrexate—multiple sclerosis	0.000214	0.000534	CcSEcCtD
Orlistat—Vomiting—Dexamethasone—multiple sclerosis	0.000213	0.00053	CcSEcCtD
Orlistat—Vomiting—Betamethasone—multiple sclerosis	0.000213	0.00053	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—PGR—multiple sclerosis	0.000212	0.000848	CbGpPWpGaD
Orlistat—Decreased appetite—Methotrexate—multiple sclerosis	0.000212	0.000527	CcSEcCtD
Orlistat—Rash—Betamethasone—multiple sclerosis	0.000211	0.000526	CcSEcCtD
Orlistat—Rash—Dexamethasone—multiple sclerosis	0.000211	0.000526	CcSEcCtD
Orlistat—Dermatitis—Dexamethasone—multiple sclerosis	0.000211	0.000525	CcSEcCtD
Orlistat—Dermatitis—Betamethasone—multiple sclerosis	0.000211	0.000525	CcSEcCtD
Orlistat—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.00021	0.000524	CcSEcCtD
Orlistat—Fatigue—Methotrexate—multiple sclerosis	0.00021	0.000523	CcSEcCtD
Orlistat—PNLIP—Disease—CD86—multiple sclerosis	0.00021	0.00084	CbGpPWpGaD
Orlistat—Headache—Betamethasone—multiple sclerosis	0.00021	0.000522	CcSEcCtD
Orlistat—Headache—Dexamethasone—multiple sclerosis	0.00021	0.000522	CcSEcCtD
Orlistat—Asthenia—Prednisone—multiple sclerosis	0.000209	0.000521	CcSEcCtD
Orlistat—DAGLB—Hemostasis—TGFB1—multiple sclerosis	0.000209	0.000837	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—TGFB1—multiple sclerosis	0.000209	0.000837	CbGpPWpGaD
Orlistat—Pain—Methotrexate—multiple sclerosis	0.000208	0.000519	CcSEcCtD
Orlistat—FASN—Disease—CD28—multiple sclerosis	0.000208	0.000833	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—POMC—multiple sclerosis	0.000208	0.000833	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—POMC—multiple sclerosis	0.000208	0.000833	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CXCR3—multiple sclerosis	0.000208	0.000832	CbGpPWpGaD
Orlistat—Pruritus—Prednisone—multiple sclerosis	0.000206	0.000514	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—CD28—multiple sclerosis	0.000206	0.000824	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—MAPK1—multiple sclerosis	0.000205	0.000821	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—MAPK1—multiple sclerosis	0.000205	0.000821	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—CCL2—multiple sclerosis	0.000203	0.000815	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—CCL2—multiple sclerosis	0.000203	0.000815	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CXCL10—multiple sclerosis	0.000203	0.000812	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CXCL10—multiple sclerosis	0.000203	0.000812	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CCR2—multiple sclerosis	0.000202	0.000809	CbGpPWpGaD
Orlistat—Feeling abnormal—Methotrexate—multiple sclerosis	0.000201	0.0005	CcSEcCtD
Orlistat—Diarrhoea—Prednisone—multiple sclerosis	0.000199	0.000497	CcSEcCtD
Orlistat—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000199	0.000496	CcSEcCtD
Orlistat—Nausea—Dexamethasone—multiple sclerosis	0.000199	0.000495	CcSEcCtD
Orlistat—Nausea—Betamethasone—multiple sclerosis	0.000199	0.000495	CcSEcCtD
Orlistat—Urticaria—Methotrexate—multiple sclerosis	0.000193	0.000482	CcSEcCtD
Orlistat—FASN—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	0.000193	0.000774	CbGpPWpGaD
Orlistat—Dizziness—Prednisone—multiple sclerosis	0.000193	0.00048	CcSEcCtD
Orlistat—Abdominal pain—Methotrexate—multiple sclerosis	0.000193	0.00048	CcSEcCtD
Orlistat—Body temperature increased—Methotrexate—multiple sclerosis	0.000193	0.00048	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—CNR1—multiple sclerosis	0.000186	0.000747	CbGpPWpGaD
Orlistat—PNLIP—Disease—CCR5—multiple sclerosis	0.000186	0.000745	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—RGS1—multiple sclerosis	0.000186	0.000745	CbGpPWpGaD
Orlistat—Vomiting—Prednisone—multiple sclerosis	0.000185	0.000462	CcSEcCtD
Orlistat—DAGLB—Signaling by GPCR—TYK2—multiple sclerosis	0.000185	0.00074	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—TYK2—multiple sclerosis	0.000185	0.00074	CbGpPWpGaD
Orlistat—Rash—Prednisone—multiple sclerosis	0.000184	0.000458	CcSEcCtD
Orlistat—Dermatitis—Prednisone—multiple sclerosis	0.000184	0.000457	CcSEcCtD
Orlistat—Headache—Prednisone—multiple sclerosis	0.000183	0.000455	CcSEcCtD
Orlistat—PNLIP—Disease—HLA-A—multiple sclerosis	0.000181	0.000726	CbGpPWpGaD
Orlistat—Hypersensitivity—Methotrexate—multiple sclerosis	0.000179	0.000447	CcSEcCtD
Orlistat—DAGLA—Signaling Pathways—CD86—multiple sclerosis	0.000177	0.00071	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CD86—multiple sclerosis	0.000177	0.00071	CbGpPWpGaD
Orlistat—FASN—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	0.000176	0.000706	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—GPR65—multiple sclerosis	0.000176	0.000706	CbGpPWpGaD
Orlistat—Asthenia—Methotrexate—multiple sclerosis	0.000175	0.000435	CcSEcCtD
Orlistat—DAGLA—Signaling Pathways—CCL5—multiple sclerosis	0.000174	0.000699	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CCL5—multiple sclerosis	0.000174	0.000699	CbGpPWpGaD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—STAT3—multiple sclerosis	0.000174	0.000695	CbGpPWpGaD
Orlistat—Nausea—Prednisone—multiple sclerosis	0.000173	0.000431	CcSEcCtD
Orlistat—Pruritus—Methotrexate—multiple sclerosis	0.000172	0.000429	CcSEcCtD
Orlistat—PLA2G4A—Signaling Pathways—LINGO1—multiple sclerosis	0.00017	0.000683	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—IL2—multiple sclerosis	0.000169	0.000678	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—IL2—multiple sclerosis	0.000169	0.000678	CbGpPWpGaD
Orlistat—PNLIP—Disease—APOE—multiple sclerosis	0.000169	0.000678	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—ITGA4—multiple sclerosis	0.000168	0.000674	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CXCL10—multiple sclerosis	0.000168	0.000673	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—IFNB1—multiple sclerosis	0.000167	0.000669	CbGpPWpGaD
Orlistat—Diarrhoea—Methotrexate—multiple sclerosis	0.000167	0.000415	CcSEcCtD
Orlistat—FASN—Metabolism—BCHE—multiple sclerosis	0.000167	0.000667	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CYP24A1—multiple sclerosis	0.000164	0.000658	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CYP27B1—multiple sclerosis	0.000164	0.000658	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—SPP1—multiple sclerosis	0.000162	0.000647	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—SPP1—multiple sclerosis	0.000162	0.000647	CbGpPWpGaD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—MYC—multiple sclerosis	0.000161	0.000646	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—ALB—multiple sclerosis	0.000161	0.000646	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CCR1—multiple sclerosis	0.000161	0.000646	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CXCL13—multiple sclerosis	0.000161	0.000646	CbGpPWpGaD
Orlistat—Dizziness—Methotrexate—multiple sclerosis	0.000161	0.000401	CcSEcCtD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	0.000161	0.000643	CbGpPWpGaD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—MAPK1—multiple sclerosis	0.000158	0.000632	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CCR5—multiple sclerosis	0.000157	0.000629	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CCR5—multiple sclerosis	0.000157	0.000629	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—IL2RA—multiple sclerosis	0.000155	0.00062	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—IL2RA—multiple sclerosis	0.000155	0.00062	CbGpPWpGaD
Orlistat—Vomiting—Methotrexate—multiple sclerosis	0.000155	0.000386	CcSEcCtD
Orlistat—DAGLB—Signaling by GPCR—IL2—multiple sclerosis	0.000154	0.000616	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—IL2—multiple sclerosis	0.000154	0.000616	CbGpPWpGaD
Orlistat—Rash—Methotrexate—multiple sclerosis	0.000154	0.000382	CcSEcCtD
Orlistat—Dermatitis—Methotrexate—multiple sclerosis	0.000153	0.000382	CcSEcCtD
Orlistat—PNLIP—Disease—CD80—multiple sclerosis	0.000153	0.000613	CbGpPWpGaD
Orlistat—Headache—Methotrexate—multiple sclerosis	0.000153	0.00038	CcSEcCtD
Orlistat—PLA2G4A—Metabolism—GPC5—multiple sclerosis	0.00015	0.000602	CbGpPWpGaD
Orlistat—FASN—Disease—CD86—multiple sclerosis	0.000148	0.000594	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TAGAP—multiple sclerosis	0.000148	0.000592	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CD86—multiple sclerosis	0.000147	0.000588	CbGpPWpGaD
Orlistat—Nausea—Methotrexate—multiple sclerosis	0.000145	0.00036	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—CCL5—multiple sclerosis	0.000145	0.000579	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—APOE—multiple sclerosis	0.000143	0.000573	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—APOE—multiple sclerosis	0.000143	0.000573	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—APOE—multiple sclerosis	0.000142	0.000567	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—SPP1—multiple sclerosis	0.000134	0.000536	CbGpPWpGaD
Orlistat—FASN—Disease—CCR5—multiple sclerosis	0.000132	0.000527	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—IL2—multiple sclerosis	0.000131	0.000524	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CCR5—multiple sclerosis	0.00013	0.000522	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CD80—multiple sclerosis	0.000129	0.000518	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CD80—multiple sclerosis	0.000129	0.000518	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—S1PR1—multiple sclerosis	0.000129	0.000517	CbGpPWpGaD
Orlistat—PNLIP—Disease—TYK2—multiple sclerosis	0.000129	0.000517	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—IL2RA—multiple sclerosis	0.000128	0.000514	CbGpPWpGaD
Orlistat—FASN—Disease—HLA-A—multiple sclerosis	0.000128	0.000514	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—GPC5—multiple sclerosis	0.000126	0.000503	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—RRM1—multiple sclerosis	0.000124	0.000499	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—POMC—multiple sclerosis	0.000123	0.000492	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—POMC—multiple sclerosis	0.000123	0.000492	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—POMC—multiple sclerosis	0.000122	0.000488	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CCL2—multiple sclerosis	0.00012	0.000481	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CCL2—multiple sclerosis	0.00012	0.000481	CbGpPWpGaD
Orlistat—FASN—Disease—APOE—multiple sclerosis	0.00012	0.000479	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—APOE—multiple sclerosis	0.000118	0.000475	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—MAPK1—multiple sclerosis	0.000118	0.000471	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—MAPK1—multiple sclerosis	0.000118	0.000471	CbGpPWpGaD
Orlistat—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000118	0.000471	CbGpPWpGaD
Orlistat—PNLIP—Disease—CD4—multiple sclerosis	0.000117	0.000468	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—IL2RA—multiple sclerosis	0.000115	0.00046	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	0.000115	0.00046	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CCL3—multiple sclerosis	0.000115	0.00046	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	0.000115	0.000459	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	0.000112	0.00045	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—ALB—multiple sclerosis	0.000111	0.000444	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PTGER4—multiple sclerosis	0.000111	0.000443	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—RGS1—multiple sclerosis	0.00011	0.00044	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—TYK2—multiple sclerosis	0.000109	0.000437	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—TYK2—multiple sclerosis	0.000109	0.000437	CbGpPWpGaD
Orlistat—FASN—Disease—CD80—multiple sclerosis	0.000108	0.000433	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CD80—multiple sclerosis	0.000107	0.000429	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	0.000107	0.000429	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CXCR3—multiple sclerosis	0.000107	0.000428	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—GPR65—multiple sclerosis	0.000104	0.000417	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CCR2—multiple sclerosis	0.000104	0.000416	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—TGFB1—multiple sclerosis	0.000102	0.000408	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—POMC—multiple sclerosis	0.000102	0.000408	CbGpPWpGaD
Orlistat—FASN—Metabolism—APOE—multiple sclerosis	0.0001	0.000402	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—MAPK1—multiple sclerosis	0.0001	0.000401	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CCL2—multiple sclerosis	9.96e-05	0.000399	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	9.66e-05	0.000387	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CNR1—multiple sclerosis	9.58e-05	0.000384	CbGpPWpGaD
Orlistat—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	9.53e-05	0.000382	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CCR1—multiple sclerosis	9.52e-05	0.000381	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CXCL13—multiple sclerosis	9.52e-05	0.000381	CbGpPWpGaD
Orlistat—FASN—Disease—TYK2—multiple sclerosis	9.14e-05	0.000366	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—IL2—multiple sclerosis	9.08e-05	0.000364	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—IL2—multiple sclerosis	9.08e-05	0.000364	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—TYK2—multiple sclerosis	9.04e-05	0.000362	CbGpPWpGaD
Orlistat—PNLIP—Disease—STAT3—multiple sclerosis	9.04e-05	0.000362	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—IL6—multiple sclerosis	9.03e-05	0.000362	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—IL6—multiple sclerosis	9.03e-05	0.000362	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CXCL10—multiple sclerosis	8.63e-05	0.000346	CbGpPWpGaD
Orlistat—FASN—Metabolism—POMC—multiple sclerosis	8.61e-05	0.000345	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—MMP9—multiple sclerosis	8.59e-05	0.000344	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—MMP9—multiple sclerosis	8.59e-05	0.000344	CbGpPWpGaD
Orlistat—PNLIP—Disease—MYC—multiple sclerosis	8.4e-05	0.000337	CbGpPWpGaD
Orlistat—PNLIP—Disease—TGFB1—multiple sclerosis	8.38e-05	0.000336	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—ALB—multiple sclerosis	8.31e-05	0.000333	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	8.3e-05	0.000332	CbGpPWpGaD
Orlistat—FASN—Disease—CD4—multiple sclerosis	8.26e-05	0.000331	CbGpPWpGaD
Orlistat—PNLIP—Disease—MAPK1—multiple sclerosis	8.22e-05	0.000329	CbGpPWpGaD
Orlistat—FASN—Metabolism—ALB—multiple sclerosis	7.85e-05	0.000314	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—STAT3—multiple sclerosis	7.64e-05	0.000306	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—STAT3—multiple sclerosis	7.64e-05	0.000306	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	7.56e-05	0.000303	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—IL2—multiple sclerosis	7.52e-05	0.000301	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CCL5—multiple sclerosis	7.43e-05	0.000298	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—BCHE—multiple sclerosis	7.15e-05	0.000286	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—MMP9—multiple sclerosis	7.12e-05	0.000285	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—MYC—multiple sclerosis	7.1e-05	0.000284	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—MYC—multiple sclerosis	7.1e-05	0.000284	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—TGFB1—multiple sclerosis	7.08e-05	0.000284	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—TGFB1—multiple sclerosis	7.08e-05	0.000284	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—MAPK1—multiple sclerosis	6.95e-05	0.000278	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—MAPK1—multiple sclerosis	6.95e-05	0.000278	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CCL3—multiple sclerosis	6.78e-05	0.000272	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—IL2—multiple sclerosis	6.74e-05	0.00027	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CCR5—multiple sclerosis	6.69e-05	0.000268	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—IL2RA—multiple sclerosis	6.6e-05	0.000264	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PTGER4—multiple sclerosis	6.53e-05	0.000262	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PGR—multiple sclerosis	6.43e-05	0.000258	CbGpPWpGaD
Orlistat—FASN—Disease—STAT3—multiple sclerosis	6.4e-05	0.000256	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—STAT3—multiple sclerosis	6.33e-05	0.000254	CbGpPWpGaD
Orlistat—PNLIP—Disease—IL6—multiple sclerosis	6.32e-05	0.000253	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CXCR3—multiple sclerosis	6.31e-05	0.000253	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CD28—multiple sclerosis	6.25e-05	0.00025	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CCR2—multiple sclerosis	6.14e-05	0.000246	CbGpPWpGaD
Orlistat—FASN—Disease—MYC—multiple sclerosis	5.94e-05	0.000238	CbGpPWpGaD
Orlistat—FASN—Disease—TGFB1—multiple sclerosis	5.93e-05	0.000238	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—MYC—multiple sclerosis	5.88e-05	0.000236	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—TGFB1—multiple sclerosis	5.87e-05	0.000235	CbGpPWpGaD
Orlistat—FASN—Disease—MAPK1—multiple sclerosis	5.81e-05	0.000233	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—MAPK1—multiple sclerosis	5.76e-05	0.000231	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CNR1—multiple sclerosis	5.66e-05	0.000227	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SRM—multiple sclerosis	5.46e-05	0.000219	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—IL6—multiple sclerosis	5.34e-05	0.000214	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—IL6—multiple sclerosis	5.34e-05	0.000214	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—TGFB1—multiple sclerosis	5.26e-05	0.000211	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—POMC—multiple sclerosis	5.23e-05	0.00021	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—MAPK1—multiple sclerosis	5.15e-05	0.000206	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CCL2—multiple sclerosis	5.12e-05	0.000205	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CXCL10—multiple sclerosis	5.1e-05	0.000204	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—POMC—multiple sclerosis	5.06e-05	0.000203	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—TYK2—multiple sclerosis	4.65e-05	0.000186	CbGpPWpGaD
Orlistat—FASN—Disease—IL6—multiple sclerosis	4.47e-05	0.000179	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CD86—multiple sclerosis	4.46e-05	0.000179	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—IL6—multiple sclerosis	4.42e-05	0.000177	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CCL5—multiple sclerosis	4.39e-05	0.000176	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—APOE—multiple sclerosis	4.3e-05	0.000172	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—SPP1—multiple sclerosis	4.06e-05	0.000163	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CCR5—multiple sclerosis	3.95e-05	0.000158	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IL2RA—multiple sclerosis	3.9e-05	0.000156	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—IL2—multiple sclerosis	3.87e-05	0.000155	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	3.85e-05	0.000154	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	3.85e-05	0.000154	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—POMC—multiple sclerosis	3.7e-05	0.000148	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—APOE—multiple sclerosis	3.6e-05	0.000144	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GPC5—multiple sclerosis	3.52e-05	0.000141	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—ALB—multiple sclerosis	3.37e-05	0.000135	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CD80—multiple sclerosis	3.25e-05	0.00013	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—POMC—multiple sclerosis	3.09e-05	0.000124	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CCL2—multiple sclerosis	3.02e-05	0.000121	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—MAPK1—multiple sclerosis	2.96e-05	0.000118	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—RRM1—multiple sclerosis	2.92e-05	0.000117	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TYK2—multiple sclerosis	2.75e-05	0.00011	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IL2—multiple sclerosis	2.28e-05	9.15e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—IL6—multiple sclerosis	2.27e-05	9.1e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MMP9—multiple sclerosis	2.16e-05	8.66e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—STAT3—multiple sclerosis	1.92e-05	7.7e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MYC—multiple sclerosis	1.79e-05	7.15e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TGFB1—multiple sclerosis	1.78e-05	7.14e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MAPK1—multiple sclerosis	1.75e-05	7e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—BCHE—multiple sclerosis	1.67e-05	6.71e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IL6—multiple sclerosis	1.34e-05	5.38e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—APOE—multiple sclerosis	1.01e-05	4.04e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—POMC—multiple sclerosis	8.65e-06	3.47e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ALB—multiple sclerosis	7.89e-06	3.16e-05	CbGpPWpGaD
